Advancing Therapeutic Strategies for Nonsense‐Related Diseases: From Small Molecules to Nucleic Acid‐Based Innovations
IUBMB Life · 2025
DOI: 10.1002/iub.70027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift IUBMB Life, 2025. Verfasst von Davide Ricci und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Codon, Nonsense, Genetic Diseases, Inborn, Nucleic Acids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, European Union, European Commission.
Abstract (Originalsprache)
Nonsense mutations in gene coding regions introduce an in‐frame premature termination codon (PTC) in the mRNA transcript, resulting in the early termination of translation and the production of a truncated, nonfunctional protein. The absence of protein expression and the consequent loss of essential cellular functions are responsible for the severe phenotypes in the so‐called genetic nonsense‐related diseases (NRDs), such as cystic fibrosis, hemophilia, Duchenne muscular dystrophy, Fabry disease, Choroideremia, Usher syndrome, Shwachman–Diamond syndrome, and even certain types of cancer. Nonsense mutations pose a significant challenge in the treatment of NRDs, as a specific approach directly addressing this genetic defect is currently unavailable. Developing new therapeutic strategies for nonsense suppression is a crucial goal of precision medicine. This review describes some of the most promising therapeutic approaches and emerging strategies for treating NRDs. It considered both the use of small molecules to interfere with molecular mechanisms related to nonsense mutations, such as translational readthrough‐inducing drugs (TRIDs) or inhibitors of the nonsense‐mediated decay (NMD) pathway, and also innovative approaches involving nucleic acids, such as gene editing, anticodon engineered‐tRNA (ACE‐tRNA), or mRNA‐based therapy. Future research should focus on refining these approaches and exploring integrated and personalized treatments to enhance therapeutic outcomes and ensure continuous improvement in the quality of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy.
- Department of Life Sciences and Biotechnology and LTTA Centre, University of Ferrara, Ferrara, Italy.
ORCID-Profile: Alessio Branchini, Laura Lentini
Förderung
- Ministero dell'Università e della Ricerca
- European Union
- European Commission
Zitieren
APA
Ricci, D., Cruciata, I., Fiduccia, I., Vitale, E., Corrao, F., Branchini, A., Carollo, P. S., Pibiri, I., & Lentini, L. (2025). Advancing Therapeutic Strategies for Nonsense‐Related Diseases: From Small Molecules to Nucleic Acid‐Based Innovations. IUBMB Life. https://doi.org/10.1002/iub.70027
Vancouver
Ricci D, Cruciata I, Fiduccia I, Vitale E, Corrao F, Branchini A, et al. Advancing Therapeutic Strategies for Nonsense‐Related Diseases: From Small Molecules to Nucleic Acid‐Based Innovations. IUBMB Life. 2025. doi:10.1002/iub.70027
BibTeX
@article{Ricci2025,
author = {Ricci, Davide and Cruciata, Ilenia and Fiduccia, Ignazio and Vitale, Emanuele and Corrao, Federica and Branchini, Alessio and Carollo, Pietro Salvatore and Pibiri, Ivana and Lentini, Laura},
title = {Advancing Therapeutic Strategies for Nonsense‐Related Diseases: From Small Molecules to Nucleic Acid‐Based Innovations},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.70027}
}
EUVIMED